Prab: CSV import

2025-02-13T03:59:09Z

CSV import

← Older revision		Revision as of 03:59, 13 February 2025
Line 1:		Line 1:
	~~{{Short description\|An antisense oligonucleotide drug}}~~		== Afovirsen ==
	~~{{Drugbox~~
	~~\| verifiedfields~~ = ~~changed~~
	~~\| verifiedrevid~~ = ~~477002123~~
	~~\| IUPAC_name~~ = ~~(3'-O-(2-methoxyethyl)phosphorothioate) antisense oligonucleotide~~
	~~\| image~~ = ~~Afovirsen.svg~~
	}}

	~~'''Afovirsen''' is an~~ [[~~antisense oligonucleotide]] drug that was developed for the treatment of [[cytomegalovirus]] (CMV) infections~~. ~~It is designed to inhibit the replication~~ of ~~CMV by binding to the viral [[mRNA~~]] ~~and preventing the production of essential viral proteins.~~		[[File:Afovirsen.svg\|thumb\|right\|Chemical structure of Afovirsen]]

	~~==Mechanism of Action==~~		'''Afovirsen''' is an [[antisense oligonucleotide]] that has been studied for its potential therapeutic effects in treating viral infections, particularly those caused by the [[cytomegalovirus]] (CMV). It is designed to bind to specific [[mRNA]] sequences, thereby inhibiting the expression of viral genes and reducing viral replication.
	Afovirsen ~~works~~ by ~~targeting~~ the [[~~mRNA~~]] ~~of the cytomegalovirus~~. ~~As an antisense oligonucleotide, it binds specifically~~ to ~~the complementary sequence of the viral~~ mRNA~~. This binding results in the degradation of the mRNA or the inhibition of its translation~~, thereby ~~preventing~~ the ~~synthesis~~ of viral ~~proteins necessary for the~~ replication ~~of the virus~~.

	==~~Development and Clinical Use~~==		== Mechanism of Action ==
	Afovirsen was developed as a therapeutic agent for patients with CMV infections, particularly in immunocompromised individuals such as those with [[HIV/AIDS]] or undergoing [[organ transplantation]]. The drug was designed to offer a targeted approach to inhibit viral replication with potentially fewer side effects compared to traditional antiviral drugs.

	~~==Pharmacokinetics==~~		Afovirsen works by targeting the [[mRNA]] of the cytomegalovirus, preventing the translation of viral proteins necessary for the virus's replication and survival. This is achieved through the binding of the antisense oligonucleotide to the complementary mRNA sequence, leading to the degradation of the mRNA or blocking its translation.
	~~The pharmacokinetics~~ of ~~afovirsen involve its distribution, metabolism~~, and ~~excretion in~~ the ~~body. As an~~ oligonucleotide, ~~it is typically administered via injection. The drug is designed~~ to ~~be stable in~~ the ~~bloodstream and to reach~~ the ~~target cells where CMV replication occurs~~.

	==~~Side Effects~~==		== Clinical Applications ==
	~~Like many antiviral agents~~, ~~afovirsen may have side effects~~. ~~These~~ can ~~include local reactions at~~ the ~~site of injection~~, ~~as well as systemic effects~~ such as ~~fever~~, ~~fatigue~~, and ~~gastrointestinal disturbances~~. The ~~specific side effect profile~~ of ~~afovirsen would depend on~~ the ~~dosage~~ and the ~~individual patient's response~~ to the ~~drug~~.
			Afovirsen has been primarily investigated for its use in patients with [[immunocompromised]] conditions, such as those undergoing [[organ transplantation]] or those with [[HIV/AIDS]], who are at higher risk for CMV infections. The reduction in viral load can help prevent the complications associated with CMV, such as [[retinitis]], [[pneumonia]], and [[gastroenteritis]].

			== Development and Research ==

			Research into Afovirsen has included [[clinical trials]] to assess its efficacy and safety profile. These studies aim to determine the optimal dosing regimens and to evaluate the potential side effects associated with its use. The development of antisense therapies like Afovirsen represents a novel approach in the treatment of viral infections, offering a targeted mechanism of action compared to traditional antiviral drugs.

			== Challenges and Considerations ==

			While Afovirsen shows promise, there are challenges associated with its use, including the delivery of the oligonucleotide to the target cells and the potential for off-target effects. Additionally, the development of resistance and the cost of production are important considerations in the clinical application of antisense therapies.

			== Related Pages ==

	~~==Related pages==~~
	* [[Antisense therapy]]		* [[Antisense therapy]]
	* [[Cytomegalovirus]]		* [[Cytomegalovirus]]
	* [[Antiviral drug]]
	* [[Oligonucleotide]]		* [[Oligonucleotide]]
			* [[Viral infection]]

	[[Category:Antiviral drugs]]		[[Category:Antiviral drugs]]
	[[Category:Oligonucleotides]]		[[Category:Oligonucleotides]]
	~~[[Category:Experimental drugs]]~~

	~~<gallery>~~
	~~Image:Afovirsen.svg\|Chemical structure of Afovirsen~~
	~~</gallery>~~

Prab: CSV import

2025-02-11T21:40:44Z

CSV import

New page

{{Short description|An antisense oligonucleotide drug}}
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = (3'-O-(2-methoxyethyl)phosphorothioate) antisense oligonucleotide
| image = Afovirsen.svg
}}

'''Afovirsen''' is an [[antisense oligonucleotide]] drug that was developed for the treatment of [[cytomegalovirus]] (CMV) infections. It is designed to inhibit the replication of CMV by binding to the viral [[mRNA]] and preventing the production of essential viral proteins.

==Mechanism of Action==
Afovirsen works by targeting the [[mRNA]] of the cytomegalovirus. As an antisense oligonucleotide, it binds specifically to the complementary sequence of the viral mRNA. This binding results in the degradation of the mRNA or the inhibition of its translation, thereby preventing the synthesis of viral proteins necessary for the replication of the virus.

==Development and Clinical Use==
Afovirsen was developed as a therapeutic agent for patients with CMV infections, particularly in immunocompromised individuals such as those with [[HIV/AIDS]] or undergoing [[organ transplantation]]. The drug was designed to offer a targeted approach to inhibit viral replication with potentially fewer side effects compared to traditional antiviral drugs.

==Pharmacokinetics==
The pharmacokinetics of afovirsen involve its distribution, metabolism, and excretion in the body. As an oligonucleotide, it is typically administered via injection. The drug is designed to be stable in the bloodstream and to reach the target cells where CMV replication occurs.

==Side Effects==
Like many antiviral agents, afovirsen may have side effects. These can include local reactions at the site of injection, as well as systemic effects such as fever, fatigue, and gastrointestinal disturbances. The specific side effect profile of afovirsen would depend on the dosage and the individual patient's response to the drug.

==Related pages==
* [[Antisense therapy]]
* [[Cytomegalovirus]]
* [[Antiviral drug]]
* [[Oligonucleotide]]

[[Category:Antiviral drugs]]
[[Category:Oligonucleotides]]
[[Category:Experimental drugs]]

<gallery>
Image:Afovirsen.svg|Chemical structure of Afovirsen
</gallery>

Afovirsen - Revision history

Prab: CSV import

Prab: CSV import